-
Article
Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
When a new drug or biologic product enters the market, its full spectrum of side effects is not yet fully understood, as use in the real world often uncovers nuances not suggested within the relatively narrow ...
-
Article
Open AccessWe’re not all cut from the same cloth: TAILORing treatments for children with chronic conditions
Finding the optimal treatment for a chronic condition can be a complex and lengthy endeavor for both the patient and the clinician. To address this challenge, we developed an “N-of-1” quality improvement infra...
-
Article
Reply to Ward and Colleagues’ Comment on “Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors”
-
Article
Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors
When a new drug enters the market, its full array of side effects remains to be defined. Current surveillance approaches targeting these effects remain largely reactive. There is a need for development of meth...
-
Article
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program
Metastatic cancers impose significant burdens on patients, affecting quality of life, morbidity, and mortality. Even during remission, microscopic metastases can lurk, but few therapies directly target tumor c...
-
Article
Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route
Progestogen has been investigated as a preventive intervention among women with increased preterm birth risk. Our objective was to systematically review the effectiveness of intramuscular (IM), vaginal, and or...
